Cameron J. Koch

faculty photo
Professor of Radiation Biology in Radiation Oncology
Department: Radiation Oncology

Contact information
185 John Morgan Building
3620 Hamilton Walk
Philadelphia, PA 19104-6072
Office: 215-898-0073
Fax: 215-898-0090
University of Waterloo, Ontario, Canada, 1968.
University of Waterloo, Ontario, Canada, 1969.
University of Waterloo, Ontario, Canada, 1972.
Permanent link

Description of Research Expertise

Measurement of radioresistant hypoxic tumor cells in vivo using:
•immunohistochemistry and/or flow cytometry
•non-invasive imaging
•Quantification of tissue pO2
•Control and measurement of oxygen concentration and thiols
•Quantitative Fluorescence Microscopy
•Oxidative damage (primarily sulfydryl to disulfide) of DNA repair systems
•Effects of oxygen and oxygen radicals in biological or biochemical systems
•Development of fluorine-based PET imaging methods
•Automated chemical synthesis
•Mechanisms of action of radiation sensitizing and radiation protecting agents (survival or DNA damage)
•Models for competitive reactions of radiation modifying agents
•Metabolism of thiols and nitroheterocyclics (including cytotoxicity)
•Measurement of intracellular drug concentrations

Description of Itmat Expertise

Dr. Koch is primarily interested in invasive and non-invasive detection of cancer-therapy resistance, with specific interest in determining hypoxia in tissues.

Selected Publications

Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.: Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 127(2): 391-400, Apr 2016.

Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. PLoS One. 10(7): e0133895, Jul 24 2015.

Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. J Nucl Med. 56(4): 653, Apr 2015.

Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW.: Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. Int J Cancer. 136(5), Mar 1 2015.

Koch CJ, Evans SM.: Optimizing hypoxia detection and treatment strategies. Semin Nucl Med. 45(2): 163-76, Mar 2015.

Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM.: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 7(6): 752-8, Dec 2014.

Regter S, Hedayati M, Zhang Y, Zhou H, Dalrymple S, Koch CJ, Isaacs JT, DeWeese TL: Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. Prostate. 74(8): 805-10, Jun 2014.

Sayler, E, Dolney, D, Avery, S, Koch, C: Shielding considerations for the small animal radiation research platform (SARRP). Health Phys. 104: 471-80, 2013.

Koch CJ, Jenkins WT, Jenkins KW, Yang XY, Shuman AL, Pickup S, Riehl1 CR, Paudya R, Poptani H, Evans SM: Mechanisms of Blood Flow and Hypoxia Production in Rat 9L Epigastric Tumors. Tumor Microenvironment and Therapy 1(1): 1-13, Dec 2012.

Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, Divgi C, Eskola O, Sorger JM, Stabin MG, Kachur A, Hahn SM, Grönroos TJ, Forsback S, Evans SM, Koch CJ, Minn H: Radiation dosimetry and biodistribution of the hypoxia tracer ¹⁸F-EF5 in oncologic patients. Cancer Biother Radiopharm. 27(7): 412-9, Sep 2012.

back to top
Last updated: 03/23/2016
The Trustees of the University of Pennsylvania